Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Atkins

Showing results (371-380 of 493) with videos related to

Pageof 50
Sort By:
Cancer Medicine|July 19, 2017
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation statusBenjamin Izar, William Sharfman, F Stephen Hodi, et al.
JAMIA Open|July 10, 2025
Utilizing Immuno-Oncology registry data for enhanced non-small cell lung cancer treatment predictionsYili Zhang, Shaked Lev-Ari, Jacob Zaemes, et al.
Molecular and Cellular Biology|July 26, 2002
Microarray analyses during adipogenesis: understanding the effects of Wnt signaling on adipogenesis and the roles of liver X receptor alpha in adipocyte metabolismSarah E Ross, Robin L Erickson, Isabelle Gerin, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 21, 2002
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological TherapyUlrich Keilholz, Jeffrey Weber, James H Finke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2019
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced MelanomaMeredith M Regan, Lillian Werner, Sumati Rao, et al.
Journal for Immunotherapy of Cancer|January 31, 2018
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinomaVadim S Koshkin, Pedro C Barata, Tian Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 1997
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignanciesM B Atkins, M J Robertson, M Gordon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2024
A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell CarcinomaElaine Chang, Jiaxi Zhou, Chi Song, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 14, 2016
Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell CarcinomaAndre P Fay, Guillermo de Velasco, Thai H Ho, et al.
Cancers|March 25, 2022
Transcriptional Profiling of Malignant Melanoma Reveals Novel and Potentially Targetable Gene FusionsSourat Darabi, Andrew Elliott, David R Braxton, et al.
Pageof 50

Showing results (371-380 of 493) with videos related to

Sort By:
Pageof 50
Cancer Medicine|July 19, 2017
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation statusBenjamin Izar, William Sharfman, F Stephen Hodi, et al.
JAMIA Open|July 10, 2025
Utilizing Immuno-Oncology registry data for enhanced non-small cell lung cancer treatment predictionsYili Zhang, Shaked Lev-Ari, Jacob Zaemes, et al.
Molecular and Cellular Biology|July 26, 2002
Microarray analyses during adipogenesis: understanding the effects of Wnt signaling on adipogenesis and the roles of liver X receptor alpha in adipocyte metabolismSarah E Ross, Robin L Erickson, Isabelle Gerin, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 21, 2002
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological TherapyUlrich Keilholz, Jeffrey Weber, James H Finke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2019
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced MelanomaMeredith M Regan, Lillian Werner, Sumati Rao, et al.
Journal for Immunotherapy of Cancer|January 31, 2018
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinomaVadim S Koshkin, Pedro C Barata, Tian Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 1997
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignanciesM B Atkins, M J Robertson, M Gordon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2024
A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell CarcinomaElaine Chang, Jiaxi Zhou, Chi Song, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 14, 2016
Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell CarcinomaAndre P Fay, Guillermo de Velasco, Thai H Ho, et al.
Cancers|March 25, 2022
Transcriptional Profiling of Malignant Melanoma Reveals Novel and Potentially Targetable Gene FusionsSourat Darabi, Andrew Elliott, David R Braxton, et al.
Pageof 50